definiens: shall mean all upfront, license, and technology access fees, productmilestone payments ( whether research, preclinical or developmental ), and other remuneration, however characterized(except for direct reimbursement of research or development expenditures actually incurred ), received by Licenseeunder a sublicense or other agreement with a Third Party for the use of the Patent Rights or the transfer or use ofLicensed Products by a Third Party . Any non - cash consideration received by Licensee from Sublicensees shall bevalued at its fair market value as of the date of receipt . Sublicensing Revenue shall include any premiums paid onequity investment . The following payments received from Sublicensees shall not be considered SublicensingRevenue : royalties paid for Net Sales of Licensed Products, sales of equity to Sublicensees for fair market value, reimbursement of patent costs, and money loaned to Licensee at or above the then - current prime rate . If Licenseegrants a sublicense to Patent Rights together with the grant of other intellectual property owned or controlled byLicensee, Licensee shall act in good faith to allocate an appropriate portion of the aggregate consideration to thePatent Rights, and only such portion allocated to the Patent Rights shall be treated as Sublicensing Revenue